Company news
Cambium Bio Ltd (ASX:CMB) news
Cambium Bio Ltd news releases on 6ix. Latest, Sep 16, 2026: Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®…
Press releases & updates
Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease
September 16, 2026
Cambium Bio Secures A$10.85 Million Funding Package
September 15, 2026
FY26 Appendix 4E and Annual Report
August 28, 2026
Cambium Bio Raises A$1.0 Million via Placement
July 21, 2026
FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
April 23, 2026
Half Year Report and Accounts
February 19, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 22, 2026
Cambium Bio Secures A$2.4 Million Strategic Investment
January 19, 2026
Cambium Bio Signs Strategic MoU with Benta SAS
September 5, 2025
Cambium Bio Signs US$2.0M plus Licensing Deal
September 2, 2025
FY25 Appendix 4E and Annual Report
August 29, 2025
Placement Participant Update
August 27, 2025
Cambium Bio Raises A$2.12 million
July 30, 2025
Cambium Bio : Half Year Report (December 2024)Cambium Bio Limited Half Year Report (December 2024) (Feb 27, 2025Feb 27, 2025)
February 27, 2025
FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol
February 24, 2025
Cambium Bio Successfully Closes A$3.0M Financing Round
December 4, 2024
Trading Halt
December 2, 2024
Cambium 4E and Annual Report
August 30, 2024
Notice of General Meeting/Proxy Form
May 23, 2024
Response to ASX Aware Query
May 1, 2024
Cambium Bio Raises A$3.48 Million in Strategic Placement
April 5, 2024
Regeneus Completes the Merger with Cambium
April 4, 2024
Half Yearly Report and Accounts
February 29, 2024
Regeneus enters into binding merger agreement with Cambium
February 14, 2024
Cambium Bio - Shareholder Update presentation
September 28, 2023
Appendix 4E - Preliminary final report-unaudited
August 31, 2023
Response to ASX Price Query
July 6, 2023
Merger with Cambium
April 27, 2023
Regeneus agrees to settle $2m loan
February 27, 2023
Notice of Termination of Kyocera Licence
January 31, 2023
Preliminary Final Report
August 30, 2022
Grant of ASX Waiver
February 24, 2022
Regeneus Market Update
December 21, 2021
Regeneus Announces Institutional Placement
May 6, 2021
Appendix 4C - Quarterly
April 30, 2021
Regeneus partners with Defence to treat combat casualties
April 29, 2021
Regeneus to be granted key Progenza patent in Europe
March 15, 2021
Regeneus Company Update Investor Webcast Presentation
March 2, 2021
Half-Year Results and Business Update
February 26, 2021
Appendix 4D and Half-Year Report
February 26, 2021
Regeneus to be granted new patent to target pain in Japan
February 8, 2021
Response to ASX Appendix 4C Query
February 4, 2021
Appendix 4C - Quarterly Report
January 28, 2021
Clarification on Quarterly Activity Report and Appendix 4C
November 10, 2020
CEO Appointment and Resignation
November 1, 2020
Regeneus receives $5.6M milestone payment from Kyocera
October 29, 2020
Regeneus to be granted new Sygenus patent in Canada
October 6, 2020
Regeneus receives milestone payment from Kyocera
August 28, 2020
Appendix 4E and Annual Report
August 28, 2020
Regeneus to present at FNN Virtual Investor Event
August 25, 2020